ALEMBIC PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 36.4%

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  •
  • MyStocks
MEMBER'S LOGIN

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 36.4%
Wed, 21 Aug

ALEMBIC PHARMA has announced its results for the quarter ended June 2019. Here is a detailed performance review of the same:

ALEMBIC PHARMA Quarterly Financials

No. of Mths
Qtr. Ending		3
Jun-18* 		3
Mar-19* 		3
Jun-19* 		QoQ ChangeYoY Change
Net SalesRs m8,6259,2709,4892.4%10.0%
Other incomeRs m13433-2.4%3190.0%
TurnoverRs m8,6269,3039,5222.4%10.4%
ExpensesRs m7,1157,4897,240-3.3%1.8%
Gross profitRs m1,5101,7831,96410.1%30.0%
DepreciationRs m27630035418.2%28.3%
InterestRs m165150-2.0%217.2%
Profit before taxRs m1,2201,4671,5938.6%30.6%
TaxRs m315149360141.3%14.0%
Profit after taxRs m9041,3181,233-6.4%36.4%
Gross profit margin%17.519.220.7
Effective tax rate%25.910.222.6
Net profit margin%10.514.213.0
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Reports, Regulatory Filings, Equitymaster


Year-on-Year Performance:
  • The company's operating income during the quarter grew 10.0% on a year-on-year (YoY) basis. The expenses were up by 1.8% YoY during the same period.
  • The company's operating profit increased by 30.0% YoY during the quarter. Consequently, operating profit margins witnessed a growth and stood at 20.7% in 1QFY20 as against 17.5% in 1QFY19.
  • Depreciation charges increased by 28.3% and finance costs increased by 217.2% YoY, respectively.
  • Other income increased by 3190.0% YoY during the quarter.
  • Net profit for the quarter increased by 36.4% YoY. Net profit margins during the quarter increased from 10.5% in 1QFY19 to 13.0% in 1QFY20.
Quarter-on-Quarter Performance:
  • The company's operating income during the quarter grew 2.4% on a quarter-on-quarter (QoQ) basis. The expenses were down by 3.3% QoQ during the same period.
  • The company's operating profit increased by 10.1% QoQ during the quarter. Consequently, operating profit margins witnessed a growth and stood at 20.7% in 1QFY20 as against 19.2% in 4QFY19.
  • Net profit for the quarter declined by 6.4% QoQ, while net profit margins declined from 14.2% in 4QFY19 to 13.0% in 1QFY20.

To see how ALEMBIC PHARMA has performed over the last eight quarters,please visit here.

ALEMBIC PHARMA Share Price Performance

Over the last one year,ALEMBIC PHARMA share price has moved down from Rs 589.3 to Rs 518.0, registering a Loss of Rs 71.3 or around 12.1%.

Meanwhile, the S&P BSE HEALTHCARE Index is trading at Rs 12,504.9 (down 0.2%). Over the last one year it has moved down from 15,302.1 to 12,504.9, a gain of 2,797 points (down 18.3%).

Overall, the S&P BSE SENSEX is down 2.5% over the year.

Current Valuations

At the current price of Rs 518.0, the price to earnings (P/E) ratio of ALEMBIC PHARMA stands at 15.6 times its trailing twelve months earnings, while its price to book value (P/BV) ratio stands at 3.6 times.

Equitymaster requests your view! Post a comment on "ALEMBIC PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 36.4%". Click here!

  

Related Views on News

ALEMBIC PHARMA Surges by 5%; BSE HEALTHCARE Index Up 0.9% (Market Updates)

Oct 17, 2019 | Updated on Oct 17, 2019

ALEMBIC PHARMA share price has surged by 5% and its current market price is Rs 550. The BSE HEALTHCARE is up by 0.9%. The top gainers in the BSE HEALTHCARE Index are ALEMBIC PHARMA (up 5.2%) and PIRAMAL ENTERPRISES (up 7.0%). The top losers are SYNGENE INTERNATIONAL (down 0.1%) and SHILPA MEDICARE (down 0.3%).

ALEMBIC PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 13, 2019 | Updated on Jun 13, 2019

Here's an analysis of the annual report of ALEMBIC PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of ALEMBIC PHARMA. Also includes updates on the valuation of ALEMBIC PHARMA.

ALEMBIC PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 28.9% (Quarterly Result Update)

May 9, 2019 | Updated on May 9, 2019

For the quarter ended March 2019, ALEMBIC PHARMA has posted a net profit of Rs 1 bn (up 28.9% YoY). Sales on the other hand came in at Rs 9 bn (up 8.6% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

ALEMBIC PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 21, 2018 | Updated on Dec 21, 2018

Here's an analysis of the annual report of ALEMBIC PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of ALEMBIC PHARMA. Also includes updates on the valuation of ALEMBIC PHARMA.

ALEMBIC PHARMA Announces Quarterly Results (2QFY19); Net Profit Up 61.0% (Quarterly Result Update)

Oct 23, 2018 | Updated on Oct 23, 2018

For the quarter ended September 2018, ALEMBIC PHARMA has posted a net profit of Rs 2 bn (up 61.0% YoY). Sales on the other hand came in at Rs 11 bn (up 42.8% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

Rebound Riches Could be Yours With These Stocks(Profit Hunter)

Oct 4, 2019

The secret to multibagger is not big businesses, but great managements... Here's how to find them to make the most of once in a decade rebound opportunity.

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


Oct 17, 2019 03:37 PM

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA 8-QTR ANALYSIS

Detailed Quarterly Results With Charts

COMPARE ALEMBIC PHARMA WITH

OTHER USEFUL LINKS

MARKET STATS


ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
  • Get Equitymaster Android App on Google Play
  • Get Equitymaster iOS App on App Store
FOLLOW

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.